Prevalence and predictors of polypharmacy among community-based individuals with traumatic spinal cord injury

The Journal of Spinal Cord Medicine, 2023 · DOI: 10.1080/10790268.2021.2008700 · Published: January 1, 2023

Simple Explanation

This study aimed to find out how common polypharmacy is among people with traumatic spinal cord injuries (TSCI) who live in the community. Polypharmacy is when someone takes five or more medicines each day. The study also looked at what might make someone more likely to be on multiple medications. The researchers checked things like how severe the spinal cord injury was, how well people could do daily tasks, and any other health problems they had. They used special scales to measure these things. By looking at all this information, they could see what factors were linked to taking many different medicines. The study found that polypharmacy is common in people with TSCI. Also, people with complete injuries, older individuals, and those who have had the injury for a longer time were more likely to be taking multiple medications. These findings can help doctors understand who is at risk for polypharmacy and potentially reduce the number of medicines they take.

Study Duration
Between December 2014 and 2016
Participants
75 patients with traumatic spinal cord injury
Evidence Level
Cross-sectional study

Key Findings

  • 1
    The study found that 50.7% of the patients with chronic traumatic SCI had polypharmacy.
  • 2
    The predictors of polypharmacy were completeness of injury, advancing age, and longer injury duration.
  • 3
    The most frequently used drug combination was the combination of anti-spasticity drugs, anti-muscarinic drugs, and gabapentinoid drugs for neuropathic pain.

Research Summary

This study investigated the rate and predictors of polypharmacy in community-living individuals with traumatic spinal cord injury (TSCI). Seventy-five patients with TSCI for ≥12 months were included, and assessments covered demographic features, injury severity (AIS), functional status (SCIM III), and comorbidities (CIRS). The study found that 50.7% of patients had polypharmacy. Regression analysis identified complete injury (OR = 7.491), advancing age (OR = 1.061), and injury duration (OR = 1.020) as significant predictors of polypharmacy. The conclusion highlights that more than half of the patients with chronic traumatic SCI experienced polypharmacy. The predictors identified can help clinicians to identify at-risk individuals.

Practical Implications

Risk Assessment

Clinicians should be aware of the high prevalence of polypharmacy in patients with chronic traumatic SCI.

Targeted Intervention

Targeted interventions should focus on individuals with complete injuries, advancing age, and longer injury duration to manage their medication regimens.

Medication Review

Regular medication reviews are necessary to minimize the risks associated with polypharmacy, such as drug interactions and side effects, and to optimize patient outcomes.

Study Limitations

  • 1
    Cross-sectional design limits the ability to assess drug side effects and interactions.
  • 2
    Lack of information about the effects of polypharmacy on rehabilitation outcomes.
  • 3
    Being a single-center study limits the generalizability of the findings.

Your Feedback

Was this summary helpful?